These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 25472998

  • 1. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
    Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L.
    Clin Cancer Res; 2015 Feb 01; 21(3):611-21. PubMed ID: 25472998
    [Abstract] [Full Text] [Related]

  • 2. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.
    J Immunother; 2011 Apr 01; 34(3):236-50. PubMed ID: 21389874
    [Abstract] [Full Text] [Related]

  • 3. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.
    PLoS One; 2013 Apr 01; 8(4):e60031. PubMed ID: 23560068
    [Abstract] [Full Text] [Related]

  • 4. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.
    Cancer Discov; 2012 Jul 01; 2(7):608-23. PubMed ID: 22719018
    [Abstract] [Full Text] [Related]

  • 5. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.
    Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C.
    Clin Cancer Res; 2017 Dec 01; 23(23):7263-7275. PubMed ID: 28947567
    [Abstract] [Full Text] [Related]

  • 6. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.
    J Immunother; 2010 May 01; 33(4):371-81. PubMed ID: 20386469
    [Abstract] [Full Text] [Related]

  • 7. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
    Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA.
    J Immunother Cancer; 2016 May 01; 4():61. PubMed ID: 27777771
    [Abstract] [Full Text] [Related]

  • 8. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
    Teijeira A, Labiano S, Garasa S, Etxeberria I, Santamaría E, Rouzaut A, Enamorado M, Azpilikueta A, Inoges S, Bolaños E, Aznar MA, Sánchez-Paulete AR, Sancho D, Melero I.
    Cancer Immunol Res; 2018 Jul 01; 6(7):798-811. PubMed ID: 29678874
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
    Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, Paek HN, Suh JH, Cho HR, Kwon B, Kwon BS, Kim BS.
    Immunol Cell Biol; 2005 Aug 01; 83(4):344-51. PubMed ID: 16033529
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C.
    J Immunother Cancer; 2021 May 01; 9(5):. PubMed ID: 34021033
    [Abstract] [Full Text] [Related]

  • 12. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD.
    Breast Cancer Res Treat; 2003 Aug 01; 80(3):275-85. PubMed ID: 14503800
    [Abstract] [Full Text] [Related]

  • 13. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N, Andersen MH, Wenandy L, Dombernowsky SL, Kiss K, Sørensen CH, Therkildsen MH, Von Buchwald C, Andersen E, Straten PT, Svane IM.
    Cytotherapy; 2011 Aug 01; 13(7):822-34. PubMed ID: 21428850
    [Abstract] [Full Text] [Related]

  • 14. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM, Beutel LD, Nayak SK, Dillman RO.
    J Immunother; 1997 Sep 01; 20(5):377-86. PubMed ID: 9336745
    [Abstract] [Full Text] [Related]

  • 15. 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.
    Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.
    Cancer Immunol Res; 2017 Jun 01; 5(6):439-445. PubMed ID: 28473315
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
    Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA.
    J Immunol; 2013 Sep 01; 191(5):2217-25. PubMed ID: 23904171
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.
    Clin Immunol; 2007 Oct 01; 125(1):76-87. PubMed ID: 17706463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.